CCM-101

City of Cambridge

R-50.

IN CITY COUNCIL

September 10, 2001

COUNCILLOR SULLIVAN
COUNCILLOR BORN
COUNCILLOR BRAUDE
COUNCILLOR DAVIS
COUNCILLOR DECKER
MAYOR GALLUCCIO
VICE MAYOR MAHER
COUNCILLOR REEVES
COUNCILLOR TOOMEY

RESOLVED: That the City Council go on record congratulating Transkaryotic Therapies, Inc. (TKI) for being awarded a broad patent for its novel method of producing proteins for use as drugs; and be it further

RESOLVED: That the City Clerk be and hereby is requested to forward a suitably engrossed copy of this resolution to Transkaryotic Therapies, Inc. on behalf of the entire City Council.

In City Council September 10, 2001.
Adopted by the affirmative vote of nine members.
Attest:- D. Margaret Drury, City Clerk.

A true copy;

ATTEST:- D. Margaret Drury

D. Margaret Drury
City Clerk

8/14

150

MAS

Re: That the City Council go on record congratulating Transkaryotic Therapies, Inc. (TKI) for being awarded a broad patent for its novel method of producing proteins for use as drugs; and be it further

Re: SEC

Transkaryotic wins broad patent for protein drug technology

The US Patent and Trademark Office yesterday awarded Transkaryotic Therapies Inc. of Cambridge a broad patent for its novel method of producing proteins for use as drugs.

A lengthy patent application, comprising 356 separate claims, had been filed in 1995. "This further expands our intellectual property portfolio as it relates to our Gene-Activated protein and Transkaryotic therapy gene therapy platforms," said Dr. Richard F. Selden, TKT's president and chief executive.

The patent presents an interesting twist for TKT, which this year lost the most closely watched patent infringement trial ever in the biotechnology industry. Amgen Inc. of Thousand Oaks, Calif., produced its anemia drug, Epogen, in hamster ovary cells into which it had introduced human genes. It sells about $4 billion worth of the drug a year.

TKT produced its version of the drug in human cells using its gene activation technology. Instead of taking desired genes and cloning them into animal or bacteria cells, TKT says it has found a way to "switch on" the targeted genes within human cells. That way, the human cells produce the desired protein.

In January, a US District Court judge ruled that TKT infringed on the Amgen patent. A British court ruled in favor of Amgen in April.

TKT is appealing both the American and the British court decisions.

The new patent appears to validate TKT's method of producing drugs.

But the patent could put TKT on the defensive, needing to defend its intellectual property from copycats. TKT officials yesterday declined to discuss how they would commercialize the patent.

TKT shares yesterday gained 19 cents to close at $31.99 on a volume of 208,000 shares.

JEFFREY KRASNER

8/15/01 Boz-Fuz

2001 AUG 15 A 9:31

OFFICE OF THE CITY CLERK
CAMBRIDGE, MASSACHUSETTS

Councillor Sullivan

Congrats

today's Globe

p. C4

Protein Drug

Technology

mc

CCM-101

City of Cambridge

R-50.

IN CITY COUNCIL

September 10, 2001

COUNCILLOR SULLIVAN

RESOLVED: That the City Council go on record congratulating Transkaryotic Therapies, Inc. (TKI) for being awarded a broad patent for its novel method of producing proteins for use as drugs; and be it further

RESOLVED: That the City Clerk be and hereby is requested to forward a suitably engrossed copy of this resolution to Transkaryotic Therapies, Inc. on behalf of the entire City Council.

1195R

Resolution #50

Congratulations to Transkaryotic Therapies, Inc. for being awarded a broad patent for its novel method of producing proteins for use as drugs.

Councillor Sullivan

In City Council September 10, 2001

ORDER ADOPTED